Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Balaxi Pharmaceuticals Ltd
Quarter-by-quarter operating performance
| Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 86.58 | 80.68 | 65.96 | 54.72 | 60.79 | 59.83 | 65.62 | 77.38 | 73.29 | 76.27 | 70.74 | 56.18 | 72.54 |
| Expenses + | 71.29 | 67.93 | 57.12 | 43.96 | 47.14 | 46.36 | 55.53 | 66.79 | 69.30 | 63.72 | 66.58 | 55.02 | 69.45 |
| Operating Profit | 15.29 | 12.75 | 8.84 | 10.76 | 13.65 | 13.47 | 10.09 | 10.59 | 3.99 | 12.55 | 4.16 | 1.16 | 3.09 |
| OPM % | 17.66% | 15.80% | 13.40% | 19.66% | 22.45% | 22.51% | 15.38% | 13.69% | 5.44% | 16.45% | 5.88% | 2.06% | 4.26% |
| Other Income + | -4.57 | -0.22 | -47.68 | 5.93 | 1.51 | -0.70 | -1.85 | -4.11 | 3.94 | -1.69 | -1.78 | 1.59 | 0.10 |
| Interest | 0.01 | 0.27 | 0.29 | 0.37 | 0.41 | 0.61 | 0.37 | 0.45 | 1.38 | 0.74 | 1.01 | 0.89 | 1.02 |
| Depreciation | 0.19 | 1.19 | 0.29 | 0.66 | 0.48 | 0.67 | 0.49 | 0.46 | 0.48 | 0.46 | 0.46 | 0.48 | 0.56 |
| Profit before tax | 10.52 | 11.07 | -39.42 | 15.66 | 14.27 | 11.49 | 7.38 | 5.57 | 6.07 | 9.66 | 0.91 | 1.38 | 1.61 |
| Tax % | 21.86% | 26.83% | 4.90% | 7.92% | 4.77% | 4.87% | 12.06% | 17.41% | 11.70% | 10.56% | 67.03% | 84.06% | 80.75% |
| Net Profit + | 8.23 | 8.10 | -41.34 | 14.43 | 13.59 | 10.93 | 6.48 | 4.59 | 5.36 | 8.64 | 0.29 | 0.21 | 0.31 |
| EPS in Rs | 1.64 | 1.59 | -8.07 | 2.82 | 2.65 | 2.01 | 1.17 | 0.83 | 0.97 | 1.57 | 0.05 | 0.04 | 0.06 |
Financials of Balaxi Pharmaceuticals Ltd
Annual income statement trend
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Sales + | 14 | 46 | 231 | 279 | 336 | 241 | 293 | 276 |
| Expenses + | 12 | 37 | 189 | 229 | 279 | 197 | 260 | 255 |
| Operating Profit | 2 | 8 | 43 | 51 | 57 | 45 | 32 | 21 |
| OPM % | 11% | 18% | 18% | 18% | 17% | 18% | 11% | 8% |
| Other Income + | 1 | 1 | 2 | 5 | 3 | -38 | 2 | -2 |
| Interest | 0 | 0 | 0 | 1 | 1 | 3 | 4 | 4 |
| Depreciation | 0 | 0 | 0 | 1 | 2 | 2 | 2 | 2 |
| Profit before tax | 2 | 9 | 44 | 55 | 57 | 2 | 29 | 14 |
| Tax % | 19% | 31% | 14% | 13% | 19% | 219% | 13% | |
| Net Profit + | 2 | 6 | 38 | 48 | 46 | -2 | 25 | 9 |
| EPS in Rs | 1.30 | 1.22 | 7.63 | 9.53 | 9.03 | -0.44 | 4.54 | 1.72 |
| Dividend Payout % | 0% | 0% | 0% | 1% | 0% | 0% | 0% |
Financials of Balaxi Pharmaceuticals Ltd
Capital structure and asset base
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3 | 10 | 10 | 10 | 10 | 11 | 11 | 11 |
| Reserves | 0 | 18 | 55 | 103 | 173 | 190 | 221 | 227 |
| Borrowings + | 0 | 0 | 4 | 4 | 13 | 19 | 53 | 57 |
| Other Liabilities + | 3 | 8 | 31 | 60 | 43 | 38 | 25 | 28 |
| Total Liabilities | 6 | 36 | 100 | 176 | 240 | 258 | 310 | 322 |
| Fixed Assets + | 0 | 0 | 2 | 29 | 41 | 41 | 41 | 45 |
| CWIP | 0 | 0 | 0 | 1 | 3 | 2 | 22 | 34 |
| Investments | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 |
| Other Assets + | 6 | 36 | 94 | 147 | 195 | 215 | 247 | 244 |
| Total Assets | 6 | 36 | 100 | 176 | 240 | 258 | 310 | 322 |
Financials of Balaxi Pharmaceuticals Ltd
Operating, investing and financing cash movement
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | -2 | -14 | 0 | 34 | 6 | 5 | -35 |
| Cash from Investing Activity + | -0 | -0 | -6 | -28 | -11 | -1 | -22 |
| Cash from Financing Activity + | 0 | 18 | 4 | -0 | 26 | 30 | 34 |
| Net Cash Flow | -2 | 4 | -2 | 6 | 21 | 34 | -23 |
| Free Cash Flow | -2 | -14 | -3 | 7 | -9 | 4 | -57 |
| CFO/OP | -97% | -161% | 6% | 78% | 32% | 26% | -98% |
Financials of Balaxi Pharmaceuticals Ltd
Working capital efficiency and return ratios
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 147 | 238 | 121 | 36 | 57 | 84 | 138 |
| Inventory Days | 9 | 29 | 184 | 189 | 233 | 173 | |
| Days Payable | 64 | 53 | 92 | 62 | 82 | 36 | |
| Cash Conversion Cycle | 147 | 183 | 97 | 129 | 184 | 235 | 275 |
| Working Capital Days | 82 | 181 | 91 | 92 | 122 | 142 | 186 |
| ROCE % | 57% | 93% | 60% | 37% | 21% | 13% |